NasdaqGS - Delayed Quote USD

Vaxcyte, Inc. (PCVX)

65.57 -1.22 (-1.83%)
At close: May 9 at 4:00 PM EDT
65.57 0.00 (0.00%)
After hours: May 9 at 4:02 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Grant E. Pickering M.B.A. Co-Founder, CEO & Director 1.13M 1.2M 1968
Mr. Andrew L. Guggenhime M.B.A. President & CFO 820.81k 1.9M 1968
Mr. James Wassil M.B.A., M.S. Executive VP & COO 521.05k 943.62k 1969
Mr. Mikhail Eydelman J.D. Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary 684.62k 930.64k 1982
Dr. Ashish Khanna M.B.A., Ph.D. Co-Founder -- -- 1972
Dr. Jeff Fairman Ph.D. Co-Founder & VP of Research -- -- 1964
Ms. Elvia Cowan Senior VP of Finance & Principal Accounting Officer -- -- 1973
Ms. Janet Graesser Senior Vice President of Corporate Communications & Investor Relations -- -- --
Ms. Whitney Jones Chief People Officer -- -- --
Mr. Paul W. Sauer M.B.A. Senior Vice President of Process Development & Manufacturing 608.96k -- 1961

Vaxcyte, Inc.

825 Industrial Road
Suite 300
San Carlos, CA 94070
United States
650 837 0111 https://vaxcyte.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
254

Description

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Corporate Governance

Vaxcyte, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 7. The pillar scores are Audit: 3; Board: 4; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 10, 2024 - May 15, 2024
Vaxcyte, Inc. Earnings Call

Related Tickers

NUVL Nuvalent, Inc.
67.52
-0.03%
 
ITOS iTeos Therapeutics, Inc.
12.19
-0.08%
 
LEGN Legend Biotech Corporation
45.52
-0.44%
 
ASND Ascendis Pharma A/S
133.13
-0.60%
 
RVMD Revolution Medicines, Inc.
37.45
-2.24%
 
IDYA IDEAYA Biosciences, Inc.
40.64
-1.86%
 
KYMR Kymera Therapeutics, Inc.
38.61
+0.29%
 
ACLX Arcellx, Inc.
52.73
+0.92%
 
RLAY Relay Therapeutics, Inc.
6.31
-3.07%
 
IMVT Immunovant, Inc.
29.70
-0.20%